What do systematic reviews say?

Aldosterone antagonists vs ACEi or ACEi plus ARB

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs ACEi or ACEi plus ARB

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists showed no clear difference in death compared with placebo or standard care (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.58 [0.1, 3.5]
  3 studies · 421 participants
  Low

Aldosterone antagonists vs ACEi or ACEi plus ARB

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs ACEi or ACEi plus ARB

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 465 participants
  Very low

Aldosterone antagonists vs ACEi or ACEi plus ARB

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Low

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists showed no clear difference in cardiovascular events compared with placebo or standard care (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.95 [0.26, 3.56]
  3 studies · 1067 participants
  Low

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists showed no clear difference in doubling serum creatinine compared with placebo or standard care (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 1.3 [0.69, 2.44]
  2 studies · 875 participants
  Low

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists probably leads to higher AKI compared with placebo or standard care (moderate certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 2.04 [1.05, 3.97]
  5 studies · 1446 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 1193 participants
  Very low

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 1144 participants
  Low

Aldosterone antagonists vs diuretics

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (any cause) compared with control (placebo or standard care) (moderate certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 0.45 [0.3, 0.67]
  9 studies · 1119 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 0.37 [0.22, 0.64]
  6 studies · 908 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower cardiovascular and cerebrovascular morbidity compared with control (placebo or standard care) (moderate certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 0.38 [0.18, 0.76]
  3 studies · 328 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 1.41 [0.72, 2.78]
  9 studies · 981 participants
  Low

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) probably leads to higher gynaecomastia compared with control (placebo or standard care) (moderate certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 5.95 [1.93, 18.28]
  4 studies · 768 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 562 participants
  Low

Aldosterone antagonists vs placebo

It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  RR 0.61 [0.06, 6.59]
  2 studies · 34 participants
  Very low

Aldosterone antagonists vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found